Información de la revista
Vol. 24. Núm. 5.
Páginas 352 (mayo 2006)
Vol. 24. Núm. 5.
Páginas 352 (mayo 2006)
Cartas científicas
DOI: 10.1157/13089673
Acceso a texto completo
Efectos adversos agudos tras la administración de anfotericina B liposomal
Visitas
25629
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Tiphine, V. Letscher-Bru, R. Herbrecht.
Amphotericin and its new formulation: pharmacologic characteristics, clinical efficacy, and tolerability.
Transpl Infect Dis, 1 (1999), pp. 273-283
[2.]
R. Herbrecht.
The changing epidemiology of fungal infections: are the lipid- forms of amphotericin B an advance?.
Eur J Haematol, 57 (1996), pp. 12-17
[3.]
M.M. Roden, L.D. Nelson, T.A. Knudsen, P.F. Jarosinski, J.M. Starling, S.E. Shiflett, et al.
Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristic.
Clin Infect Dis, 36 (2003), pp. 1213-1220
[4.]
B. Dupont.
Overview of the lipid formulations of amphotericine.
J Antimicrob Chemother, 49 (2002), pp. 31-36
[5.]
M.D. Johnson, R.H. Drew, J.R. Perfect.
Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.
Pharmacotherapy, 18 (1998), pp. 1053-1061
[6.]
F.E. Karch, L. Lasagna.
Toward the operational identification of adverse drug reaction.
Clin Pharmacol Ther, 21 (1977), pp. 247-255
Copyright © 2006. Elsevier España S.L.. Todos los derechos reservados